Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

Exclusion criteria

• . Participation in any other clinical trial of an experimental treatment or used an investigational drug within the past 30 days.
• . Subject has a clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, hematological or psychiatric disorder(s) as determined by the Principal Investigator or designee.
• . History of diabetes mellitus or an HbA1C greater than 5.7 percent.
• . History of prior abdominal surgery or abdominal liposuction, cryolipolysis, focused ultrasound or other fat reduction procedures in or near the anterior abdomen within 12 months prior to screening.
• . History of poor or delayed wound healing such as prior wound dehiscence, chronic wound or leg ulcer.
• . History of or evidence of a genetic collagen disorder such as Ehlers-Danlos Syndrome.
• . Operating Physician is unable to design an abdominoplasty incision area of at least 25 cm wide by 12 cm tall at the center of the fusiform.
• . The presence of any abnormality of the skin within the area of the proposed abdominoplasty that, in the opinion of the PI, could interfere with the excision process or grading of the resultant surgical scar (e.g., striae gravidarum, striae distensae, excessive nevi, numerous seborrheic keratoses, tattoos, etc.).